Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Letrero

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
American Journal of Human Genetics|April 24, 2003
Resolving ATM haplotypes in whitesRichard Letrero, Barbara L Weber, Katherine L Nathanson
The Journal of Molecular Diagnostics : JMD|August 11, 2007
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanomaCynthia Spittle, M Renee Ward, Katherine L Nathanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibMelissa A Wilson, Fengmin Zhao, Richard Letrero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain MetastasesRavi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Cancer Cell|December 9, 2008
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinomaJohn D Gordan, Priti Lal, Vijay R Dondeti, et al.
Molecular and Cellular Biology|September 11, 2013
The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanomaEric K Lee, Zhaorui Lian, Kurt D'Andrea, et al.
Journal of Cutaneous Pathology|December 16, 2018
NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenibVishwas Parekh, Joseph Sobanko, Christopher J Miller, et al.
Human Molecular Genetics|May 10, 2011
A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibilityPeter A Kanetsky, Nandita Mitra, Saran Vardhanabhuti, et al.
Nature Genetics|June 2, 2009
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancerPeter A Kanetsky, Nandita Mitra, Saran Vardhanabhuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
American Journal of Human Genetics|April 24, 2003
Resolving ATM haplotypes in whitesRichard Letrero, Barbara L Weber, Katherine L Nathanson
The Journal of Molecular Diagnostics : JMD|August 11, 2007
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanomaCynthia Spittle, M Renee Ward, Katherine L Nathanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibMelissa A Wilson, Fengmin Zhao, Richard Letrero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain MetastasesRavi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Cancer Cell|December 9, 2008
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinomaJohn D Gordan, Priti Lal, Vijay R Dondeti, et al.
Molecular and Cellular Biology|September 11, 2013
The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanomaEric K Lee, Zhaorui Lian, Kurt D'Andrea, et al.
Journal of Cutaneous Pathology|December 16, 2018
NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenibVishwas Parekh, Joseph Sobanko, Christopher J Miller, et al.
Human Molecular Genetics|May 10, 2011
A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibilityPeter A Kanetsky, Nandita Mitra, Saran Vardhanabhuti, et al.
Nature Genetics|June 2, 2009
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancerPeter A Kanetsky, Nandita Mitra, Saran Vardhanabhuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
Pageof 2